Clinical breast cancer, new developments in selection and endocrine treatment of patients

[1]  J. Foekens,et al.  Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplification , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  J. Foekens,et al.  Pleiotropic actions of suramin on the proliferation of human breast‐cancer cells in vitro , 1992, International journal of cancer.

[3]  E. Riboli,et al.  Diet and gastric cancer. A case‐control study in Belgium , 1992, International journal of cancer.

[4]  J. Foekens,et al.  c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. , 1992, Cancer research.

[5]  J. Foekens,et al.  Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. , 1992, European journal of cancer.

[6]  J G Klijn,et al.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.

[7]  J. Klijn.  LH-RH agonists in the treatment of metastatic breast cancer: ten years' experience. , 1992, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[8]  B. Krauss,et al.  The relation between pharmacokinetics and endocrine effects of buserelin implants in patients with mastalgia , 1991, Clinical endocrinology.

[9]  T. Perren.  c-erbB-2 oncogene as a prognostic marker in breast cancer. , 1991, British Journal of Cancer.

[10]  W. McGuire,et al.  Follow-up study of HER-2/neu amplification in primary breast cancer. , 1991, Cancer research.

[11]  P. Chambon,et al.  pS2 expression and response to hormonal therapy in patients with advanced breast cancer. , 1991, Cancer research.

[12]  M. F. Etreby,et al.  Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  J. Foekens,et al.  Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: Preclinical and clinical studies , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  J. Foekens,et al.  Manipulation of cell cycle kinetics: Influence on the cytotoxicity of doxorubicin in human breast cancer cells , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[15]  J. Klijn,et al.  Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: Preliminary results of a double-blind randomized study of the eortic breast cancer cooperative group , 1990, Journal of Steroid Biochemistry and Molecular Biology.

[16]  W. Miller,et al.  Relationship between tumour aromatase activity, tumour characteristics and response to therapy , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[17]  J. Foekens,et al.  Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[18]  R. Blamey,et al.  Zoladex® plus tamoxifen versus zoladex® alone in pre- and peri-menopausal metastatic breast cancer , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  A. Wakeling.  Therapeutic potential of pure antioestrogens in the treatment of breast cancer , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  J. Foekens,et al.  Treatment of breast cancer with different antiprogestins: Preclinical and clinical studies , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  V. Jordan,et al.  Endocrine pharmacology of antiestrogens as antitumor agents. , 1990, Endocrine reviews.

[22]  R Beuscart,et al.  Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. , 1990, Cancer research.

[23]  M. Dowsett,et al.  The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. , 1990, British Journal of Cancer.

[24]  J. Foekens,et al.  Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. , 1990, British Journal of Cancer.

[25]  J. Foekens,et al.  Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: Relationship to egf receptors , 1990, International journal of cancer.

[26]  R. Holland,et al.  Prognostic assessment in node-negative breast cancer patients. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Foekens,et al.  Prediction of relapse and survival in breast cancer patients by pS2 protein status. , 1990, Cancer research.

[28]  M A Richards,et al.  Node negative breast cancer. , 1990, BMJ.

[29]  C. Redmond,et al.  Endocrine treatment of breast cancer in women. , 1990, Endocrine reviews.

[30]  W. Gullick.  New developments in the molecular biology of breast cancer. , 1990, European journal of cancer.

[31]  B. Szende,et al.  Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75. , 1990, Journal of the National Cancer Institute.

[32]  J. Klijn,et al.  The clinical use of somatostatin analogues in the treatment of cancer. , 1990, Bailliere's clinical endocrinology and metabolism.

[33]  E. Krenning,et al.  Clinical applications of somatostatin analogs , 1990, Trends in Endocrinology & Metabolism.

[34]  G. Nagel,et al.  Remission of metastatic breast cancer after combined somatostatin and antiprolactin treatment , 1990 .

[35]  W. McGuire,et al.  Cathepsin D and prognosis in breast cancer. , 1990, The New England journal of medicine.

[36]  A. Thompson,et al.  2. Molecular lesions in breast cancer , 1990 .

[37]  J. Foekens,et al.  Prognostic Factors in Breast Cancer , 1990 .

[38]  M. Dowsett.  Novel approaches to the endocrine therapy of breast cancer. , 1990, European journal of cancer.

[39]  J. Estève,et al.  Cancer in the European Community and its member states. , 1990, European journal of cancer.

[40]  J. Foekens,et al.  Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. , 1989, Cancer research.

[41]  T. Maudelonde,et al.  CATHEPSIN D: AN INDEPENDENT PROGNOSTIC FACTOR FOR METASTASIS OF BREAST CANCER , 1989, The Lancet.

[42]  I. Christensen,et al.  Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. , 1989, Cancer research.

[43]  J. Foekens,et al.  Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells. , 1989, British Journal of Cancer.

[44]  J. Foekens,et al.  Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. , 1989, Cancer research.

[45]  J. Foekens,et al.  Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. , 1989, Endocrinology.

[46]  A. Harris,et al.  Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer. , 1989, European journal of cancer & clinical oncology.

[47]  I. Fentiman,et al.  The endocrine prevention of breast cancer. , 1989, British Journal of Cancer.

[48]  J. Klijn,et al.  Antiprogestins, a new form of endocrine therapy for human breast cancer. , 1989, Cancer research.

[49]  J. Devlin,et al.  Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. , 1989, Cancer research.

[50]  W. McGuire.  Adjuvant therapy for node-negative breast cancer. , 1989, The New England journal of medicine.

[51]  Osborne Ck,et al.  Adjuvant treatment of node-negative breast cancer. , 1989 .

[52]  A. Schally,et al.  Characteristics and distribution of receptors for [d‐trp6]‐ luteinizing hormone‐releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer , 1989, Journal of clinical laboratory analysis.

[53]  A. Harris,et al.  Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer. , 1989, Anticancer research.

[54]  A. Schally.  Oncological applications of somatostatin analogues. , 1988, Cancer research.

[55]  J. Bonneterre,et al.  Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial. , 1988, European journal of cancer & clinical oncology.

[56]  J. Bonneterre,et al.  Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. , 1988, Cancer Research.

[57]  J. Foekens,et al.  Oestradiol enhances doxorubicin uptake and cytotoxicity in human breast cancer cells (MCF-7). , 1988, European journal of cancer & clinical oncology.

[58]  E. Rutanen,et al.  Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. , 1988, Cancer research.

[59]  J. Klijn,et al.  The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer , 1988, Cancer.

[60]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .

[61]  R. Dickson,et al.  Control of human breast cancer by estrogen, growth factors, and oncogenes. , 1988, Cancer treatment and research.

[62]  J. Klijn,et al.  Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. , 1987, Cancer treatment reports.

[63]  J. Alexieva-Figusch,et al.  Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer. , 1987, European journal of cancer & clinical oncology.

[64]  J. Farndon,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.

[65]  J. Foekens,et al.  Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. , 1987, Cancer research.

[66]  D. Hayes,et al.  New agents and new medical treatments for advanced breast cancer. , 1987, Seminars in oncology.

[67]  H. Rochefort,et al.  Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. , 1987, Cancer research.

[68]  G. Romieu,et al.  The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. , 1986, Bulletin du cancer.

[69]  J. Klijn,et al.  LHRH-agonist treatment in clinical and experimental human breast cancer. , 1985, Journal of steroid biochemistry.

[70]  K. Horwitz,et al.  Progestin action and progesterone receptor structure in human breast cancer: a review. , 1985, Recent progress in hormone research.

[71]  J. Klijn,et al.  TREATMENT WITH A LUTEINISING-HORMONE-RELEASING-HORMONE ANALOGUE (BUSERELIN) IN PREMENOPAUSAL PATIENTS WITH METASTATIC BREAST CANCER , 1982, The Lancet.

[72]  G. Hortobagyi,et al.  Prognostic factors in metastatic breast cancer treated with combination chemotherapy. , 1979, Cancer research.

[73]  O. Pearson.  Endocrine treatment of breast cancer , 1976, CA: a cancer journal for clinicians.

[74]  A. Creighton,et al.  Biochemical studies on growth‐inhibitory bisdioxopiperazines. I. Effect on dna, rna and protein synthesis in mouse‐embryo fibroblasts , 1970, International journal of cancer.